Kusne Y, Mosalem OM, Quillen J, Buckner-Petty S, Muniz M, Sartor O, Johnson GB, Childs DS, Patnaik MM. Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium<sup>-177</sup> prostate-specific antigen membrane therapy. Haematologica 2025;110(9):2187-2192; https://doi.org/10.3324/haematol.2024.286808.